Patent · US Active

Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity

US10604529B2 · kind B2 · utility

0Cited by

2References

19Claims

0Family size

Assignee

SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. · CN

Inventors

Jindi Yu · Tangxia, CN
Xianping LU · Lo Wu, CN
Zhibin Li · Yuanjiang Hani, Yi and Dai Autonomous County, CN
Lijun Xin · Longbeilingcun, CN
Jiangfei ZHU · Tangxia, CN
Chao Fu · Xi'an, CN

Key dates

Filing date	Dec 18, 2017
Grant date	Mar 31, 2020
Priority date	—
Expiry date	Dec 18, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention discloses a type of fused imidazole compound, preparation method and application thereof. The structure of the compound is shown in general formula I. The definition of each group therein is as described in the specification. These compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds can act as an IDO inhibitor for treating and/or preventing a disease having a pathological feature with IDO-mediated tryptophan metabolic pathways, for example, cancer, eye disease, autoimmune disease, psychological disorder, depression symptom, anxiety disorder and other diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.